🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed or Refractory Multiple Myeloma

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 NCT07623798Phase 31 site📍 Shanghai Innovent Biologics (Suzhou) Co. Ltd. · Tests: Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection), IBI3003, Selinexor Tab… Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma NCT07096778Phase 231 sites📍 Phoenix📍 San Francisco📍 Jacksonville CellCentric Ltd. · Tests: Inobrodib, Pomalidomide, Dexamethasone A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT05519085Phase 3266 sites📍 Los Alamitos📍 San Diego📍 West Hollywood Celgene · Tests: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site📍 Camden Roger Strair · Tests: Soursop tea Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma NCT07657312Phase 21 site📍 Columbus Naresh Bumma · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma NCT04508790Phase 28 sites📍 Duarte📍 Huntington Beach📍 Lancaster City of Hope Medical Center · Tests: Dexamethasone, Leflunomide, Pomalidomide A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients NCT06508983Phase 312 sites📍 Beijing📍 Guangzhou📍 Guangzhou Hangzhou Sumgen Biotech Co., Ltd. · Tests: SG301 Injection, SG301 placebo, pomalidomide, dexamethasone A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma NCT07681596Phase 1, Phase 212 sites📍 Duarte📍 Denver📍 Tampa AstraZeneca · Tests: AZD4045, Daratumumab, Aldesleukin A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) NCT05927571Phase 114 sites📍 Camperdown📍 Waratah📍 Adelaide Genentech, Inc. · Tests: Cevostamab, Elranatamab, Tocilizumab A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma NCT07579234Phase 31 site📍 Tianjing Shandong New Time Pharmaceutical Co., LTD · Tests: F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma NCT06083207Phase 1, Phase 213 sites📍 Wollongong📍 Heidelberg📍 Melbourne Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI3003 BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma NCT06644443Phase 1, Phase 21 site📍 Shenzhen Shenzhen University General Hospital · Tests: BCMA-GPRC5D CAR-T cells Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma NCT06209606EARLY Phase 11 site📍 West Hollywood Oncotherapeutics · Tests: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease NCT06627751Phase 21 site📍 Buffalo Roswell Park Cancer Institute · Tests: Mezigdomide, Carfilzomib, Dexamethasone, Echocardiography, Positron Emission Tomography A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma NCT06799026Phase 12 sites📍 Boston📍 Boston David Avigan · Tests: Elranatamab, GM-CSF, DC/MM Fusion Vaccine Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma NCT06940297Phase 21 site📍 Rochester Mayo Clinic · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Ciltacabtagene Autoleucel In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma NCT07715630Phase 11 site📍 Kunming Chongqing Precision Biotech Co., Ltd · Tests: Invivo CAR-T A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma NCT06574568Phase 112 sites📍 Beijing📍 Beijing📍 Foshan Excyte Biopharma Ltd · Tests: YKST02 Isatuximab in Combination With Novel Agents in RRMM - Master Protocol NCT04643002Phase 1, Phase 225 sites📍 Atlanta📍 Chicago📍 Ann Arbor Sanofi · Tests: Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma NCT05160584n/a90 sites📍 Leoben📍 Vienna📍 Edegem Janssen Pharmaceutica N.V., Belgium · Tests: No intervention A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis NCT05652335Phase 129 sites📍 Duarte📍 Irvine📍 San Francisco Janssen Research & Development, LLC · Tests: JNJ-79635322 A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) NCT07742215Phase 316 sites📍 Homyel📍 Chelyabinsk📍 Irkutsk Biocad · Tests: BCD-248 + daratumumab, Daratumumab + pomalidomide + dexamethasone Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma NCT07479979Phase 1, Phase 21 site📍 Madison Natalie Callander · Tests: Selinexor, Carfilzomib, Isatuximab, Isatuximab SC Wearable Injection System, Dexamethasone A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma NCT07518186Phase 3173 sites📍 Birmingham📍 Phoenix📍 Springdale Janssen Research & Development, LLC · Tests: JNJ-79635322, Teclistamab Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma NCT04634552Phase 278 sites📍 Birmingham📍 Little Rock📍 Duarte Janssen Research & Development, LLC · Tests: Talquetamab A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma NCT06153251Phase 119 sites📍 Birmingham📍 Duarte📍 San Francisco Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Tests: BMS-986453, Fludarabine, Cyclophosphamide Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma NCT07725406Phase 11 site📍 New York Weill Medical College of Cornell University · Tests: Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherap… A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma NCT07802717Phase 11 site📍 Rochester Vyriad, Inc. · Tests: VV169 A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy NCT06066346Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Talquetamab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy